Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. reported that Robert J. Smith and affiliated entities beneficially own a combined 50,035,000 shares of common stock, equal to 6.14% of the class. That aggregate position is composed of holdings by Energy Capital, LLC (49,700,000 shares, 6.10%) and Plato & Associates, LLC (335,000 shares, 0.04%).
The filing states Mr. Smith has sole voting and sole dispositive power over the reported shares, meaning he alone can direct voting and disposition of the position. The statement includes a certification that the securities were not acquired to change or influence control of the issuer.
Senseonics Holdings (NYSE American: SENS) has filed a Form S-3 universal shelf. The registration enables the company to issue up to $300 million in any mix of common or preferred stock, debt securities and warrants. It also includes a $100 million at-the-market (ATM) program with TD Cowen; unsold ATM capacity can be re-allocated to other offerings.
SENS is a non-accelerated, smaller reporting company with 814.7 million shares outstanding and a recent share price of $0.51 (5 Aug 2025). Proceeds are earmarked for general corporate purposes—R&D, SG&A, commercialization of the Eversense implantable CGM platform, capex and potential acquisitions—though no commitments are specified.
The filing contains no new operating results, but it signals that management may raise capital equal to roughly one-third of the current market capitalization, creating potential dilution while enhancing liquidity and strategic flexibility.
Senseonics Holdings, Inc. (NYSE American: SENS) filed a Form 8-K dated August 6, 2025 under Item 2.02 to furnish a press release (Exhibit 99.1) announcing its results for the quarter ended June 30, 2025. The press release also provides details for an accompanying conference call covering recent corporate highlights and the Company’s outlook. In accordance with SEC rules, the furnished material is not deemed “filed” for liability purposes and will not be incorporated by reference into other SEC filings. No quantitative financial data, guidance figures, or strategic updates are included in the 8-K itself.